Latest & greatest articles for schizophrenia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on schizophrenia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on schizophrenia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for schizophrenia

661. Fluoxetine, trazodone and ritanserin are more effective than placebo when used as add-on therapies for negative symptoms of schizophrenia

Fluoxetine, trazodone and ritanserin are more effective than placebo when used as add-on therapies for negative symptoms of schizophrenia Fluoxetine, trazodone and ritanserin are more effective than placebo when used as add-on therapies for negative symptoms of schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies (...) symptoms of schizophrenia Article Text Therapeutics Fluoxetine, trazodone and ritanserin are more effective than placebo when used as add-on therapies for negative symptoms of schizophrenia Statistics from Altmetric.com Question Question Are antidepressents effective add-ons to antipsychotics for the treatment of negative symptoms in chronic schizophrenia? Outcomes Change in negative symptoms. Methods Design Systematic review and meta-analysis. Data sources PubMed, Cochrane Library, EMBASE, CINAHL

2011 Evidence-Based Mental Health

662. Transcranial magnetic stimulation for the treatment of schizophrenia

Transcranial magnetic stimulation for the treatment of schizophrenia Transcranial magnetic stimulation for the treatment of schizophrenia Transcranial magnetic stimulation for the treatment of schizophrenia BlueCross BlueShield Association Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation BlueCross BlueShield Association. Transcranial magnetic stimulation (...) for the treatment of schizophrenia. Chicago: BlueCross BlueShield Association (BCBS). TEC Assessment (26)6. 2011 Authors' objectives This Assessment will review the available evidence to determine if TMS therapy is effective as an adjunctive treatment for schizophrenia. Final publication URL Additional data URL Indexing Status Subject indexing assigned by CRD MeSH Schizophrenias; Transcranial Magnetic Stimulation Language Published English Country of organisation United States English summary An English

2011 Health Technology Assessment (HTA) Database.

663. Review: depot antipsychotics may reduce risk of relapse compared with oral antipsychotics in people with schizophrenia

Review: depot antipsychotics may reduce risk of relapse compared with oral antipsychotics in people with schizophrenia Review: depot antipsychotics may reduce risk of relapse compared with oral antipsychotics in people with schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: depot antipsychotics may reduce risk of relapse compared with oral antipsychotics in people with schizophrenia Article Text Therapeutics Review

2011 Evidence-Based Mental Health

664. Review: family interventions reduce relapse or hospitalisation in people with schizophrenia

Review: family interventions reduce relapse or hospitalisation in people with schizophrenia Review: family interventions reduce relapse or hospitalisation in people with schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: family interventions reduce relapse or hospitalisation in people with schizophrenia Article Text Treatments Review: family interventions reduce relapse or hospitalisation in people with schizophrenia Statistics

2011 Evidence-Based Mental Health

665. Review: response to antipsychotics in schizophrenia in published trials of limited clinical significance

Review: response to antipsychotics in schizophrenia in published trials of limited clinical significance Review: response to antipsychotics in schizophrenia in published trials of limited clinical significance | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: response to antipsychotics in schizophrenia in published trials of limited clinical significance Article Text Therapeutics Review: response to antipsychotics

2011 Evidence-Based Mental Health

666. Smoking is associated with an increased risk of death in people aged 35?54 with schizophrenia

Smoking is associated with an increased risk of death in people aged 35?54 with schizophrenia Smoking is associated with an increased risk of death in people aged 35–54 with schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts (...) OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Smoking is associated with an increased risk of death in people aged 35–54 with schizophrenia Article Text Prognosis Smoking is associated with an increased risk of death in people aged 35–54

2011 Evidence-Based Mental Health

667. Review: people with schizophrenia or other mental illnesses have a lower rate of invasive coronary interventions after acute coronary syndrome Full Text available with Trip Pro

Review: people with schizophrenia or other mental illnesses have a lower rate of invasive coronary interventions after acute coronary syndrome Review: people with schizophrenia or other mental illnesses have a lower rate of invasive coronary interventions after acute coronary syndrome | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we (...) use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: people with schizophrenia or other mental illnesses have a lower rate of invasive coronary

2011 Evidence-Based Mental Health

668. Many people show poor adherence to their initial antipsychotic after first hospitalisation with schizophrenia

Many people show poor adherence to their initial antipsychotic after first hospitalisation with schizophrenia Many people show poor adherence to their initial antipsychotic after first hospitalisation with schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Many people show poor adherence to their initial antipsychotic after first hospitalisation with schizophrenia Article Text Prognosis Many people show poor adherence

2011 Evidence-Based Mental Health

669. Effect of antipsychotic medication alone vs combined with psychosocial intervention on outcomes of early-stage schizophrenia: A randomized, 1-year study Full Text available with Trip Pro

Effect of antipsychotic medication alone vs combined with psychosocial intervention on outcomes of early-stage schizophrenia: A randomized, 1-year study Antipsychotic drugs are limited in their ability to improve the overall outcome of schizophrenia. Adding psychosocial treatment may produce greater improvement in functional outcome than does medication treatment alone.To evaluate the effectiveness of antipsychotic medication alone vs combined with psychosocial intervention on outcomes of early (...) -stage schizophrenia.Randomized controlled trial.Ten clinical sites in China.Clinical sample of 1268 patients with early-stage schizophrenia treated from January 1, 2005, through October 31, 2007. Intervention Patients were randomly assigned to receive antipsychotic medication treatment only or antipsychotic medication plus 12 months of psychosocial intervention consisting of psychoeducation, family intervention, skills training, and cognitive behavior therapy administered during 48 group

2010 EvidenceUpdates Controlled trial quality: predicted high

670. Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis Full Text available with Trip Pro

Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis Treatment of negative symptoms in chronic schizophrenia continues to be a major clinical issue.To analyse the efficacy of add-on antidepressants for the treatment of negative symptoms of chronic schizophrenia.Systematic review and meta-analysis of randomised controlled trials comparing the effect of antidepressants and placebo on the negative symptoms of chronic schizophrenia, measured through (...) significant responses for fluoxetine, trazodone and ritanserin.Antidepressants along with antipsychotics are more effective in treating the negative symptoms of schizophrenia than antipsychotics alone.

2010 EvidenceUpdates

671. Aripiprazole (Abilify) - Schizophrenia in adolescents

Aripiprazole (Abilify) - Schizophrenia in adolescents Scottish Medicines Consortium Secretariat - Delta House 50 West Nile Street Glasgow G1 2NP Telephone 0141 225 6989 E-mail: rosie.murray@nhs.net Chairman Professor Kenneth R Paterson 1 aripiprazole 5, 10, 15, 30mg oral tablets, 10, 15mg orodisperible tablets and 1mg/1ml oral solution (Abilify®) (No: 630/10) Bristol-Myers Squibb Product Update 09 July 2010 The Scottish Medicines Consortium (SMC) has completed its assessment of the above (...) product and advises NHS Boards and Area Drug and Therapeutics Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows: ADVICE: following an abbreviated submission aripiprazole tablets, orodisperible tablets and oral solution (Abilify ® ) are accepted for restricted use within NHS Scotland. Indication under review: The treatment of schizophrenia in adolescents 15 years and older. SMC restriction: Restricted to initiation and management under the supervision of a child

2010 Scottish Medicines Consortium

672. Efficacy and safety of bupropion for smoking cessation and reduction in schizophrenia: systematic review and meta-analysis Full Text available with Trip Pro

Efficacy and safety of bupropion for smoking cessation and reduction in schizophrenia: systematic review and meta-analysis The benefits and harms of bupropion as an aid for smoking cessation in schizophrenia remain uncertain.To summarise the current evidence for efficacy and safety of bupropion as treatment for nicotine dependence in schizophrenia.Systematic review and random-effects meta-analysis of randomised controlled trials (RCTs) comparing bupropion with placebo or alternative therapeutic (...) ) or negative symptoms (P = 0.49) between the bupropion and the placebo group.Bupropion increases the rates of smoking abstinence in smokers with schizophrenia, without jeopardising their mental state.

2010 EvidenceUpdates

673. Aripiprazole - Schizophrenia

Aripiprazole - Schizophrenia CEDAC FINAL RECOMMENDATION ARIPIPRAZOLE (Abilify – Bristol-Myers Squibb Canada) Indication: Schizophrenia and Related Psychotic Disorders Recommendation: The Canadian Expert Drug Advisory Committee (CEDAC) recommends that aripiprazole not be listed. Reasons for the Recommendation: Based on a CDR systematic review of 12 randomized controlled trials, efficacy outcomes, such as the Positive and Negative Syndrome Scale scores, were similar between aripiprazole and less (...) and concerns have been raised regarding the safety and efficacy of treating these patients with antipsychotic agents. Background: Aripiprazole has a Health Canada indication for the treatment of schizophrenia and related psychotic disorders, which is the focus of this recommendation. Aripiprazole also has a Health Canada indication for the acute treatment of manic or mixed episodes in Bipolar I Disorder. It has partial agonist activity at the dopamine D2 and serotonin 5-HT1A receptors and antagonist

2010 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

674. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia (Abstract)

Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia The purpose of the present study was to evaluate the efficacy and tolerability of olanzapine long-acting injection for maintenance treatment of schizophrenia.Outpatients with schizophrenia who had maintained stability on an oral regimen of olanzapine (10, 15, or 20 mg/day) for 4 to 8 weeks were randomly assigned to 24 weeks of double-blind treatment with "low" (150 (...) treatment of schizophrenia for up to 24 weeks, with a safety profile similar to oral olanzapine except for injection-related adverse events.

2010 EvidenceUpdates Controlled trial quality: uncertain

675. A randomized, controlled trial of computer-assisted cognitive remediation for schizophrenia Full Text available with Trip Pro

A randomized, controlled trial of computer-assisted cognitive remediation for schizophrenia There is considerable interest in cognitive remediation for schizophrenia, but its essential components are still unclear. The goal of the current study was to develop a broadly targeted computer-assisted cognitive remediation program and conduct a rigorous clinical trial in a large group of schizophrenia patients.Sixty-nine people with schizophrenia or schizoaffective disorder were randomly assigned (...) . However, there were no significant benefits of cognitive remediation on any neuropsychological or functional outcome measure, either immediately after treatment or at the 3-month follow-up.Cognitive remediation for people with schizophrenia was effective in improving performance on computer exercises, but the benefits of training did not generalize to broader neuropsychological or functional outcome measures. The evidence for this treatment approach remains mixed.

2010 EvidenceUpdates Controlled trial quality: uncertain

676. Effect of Warm-Supplementing Kidney Yang (WSKY) added to risperidone on quality of life in patients with schizophrenia: a randomized controlled trial Full Text available with Trip Pro

Effect of Warm-Supplementing Kidney Yang (WSKY) added to risperidone on quality of life in patients with schizophrenia: a randomized controlled trial To evaluate the quality of life, efficacy and safety of Warm-Supplementing Kidney Yang (WSKY) added to risperidone in patients with schizophrenia.A randomized controlled trial.The outpatient and inpatient departments of three hospitals.One hundred and twenty patients with clinically diagnosed schizophrenia with predominantly negative symptoms were

2010 EvidenceUpdates Controlled trial quality: predicted high

677. Acupuncture for schizophrenia: a systematic review and meta-analysis Full Text available with Trip Pro

Acupuncture for schizophrenia: a systematic review and meta-analysis Acupuncture is one of the most popular types of complementary/alternative medicine. It is sometimes used as a treatment for schizophrenia.The objective of this review is to assess systematically the clinical evidence for or against acupuncture as a treatment for schizophrenia.We searched 20 databases from their inception to May 2009 without language restrictions. All randomised clinical trials (RCTs) of acupuncture (...) , with or without electrical stimulation or moxibustion for patients with schizophrenia were considered for inclusion.Thirteen RCTs, all originating from China, met the inclusion criteria. One RCT reported significant effects of electroacupuncture (EA) plus drug therapy for improving auditory hallucunations and positive symptom compared with sham EA plus drug therapy. Four RCTs showed significant effects of acupuncture for response rate compared with antipsychotic drugs [n = 360, relative risk (RR): 1.18, 95

2010 EvidenceUpdates

678. Cholinesterase inhibitors as adjunctive therapy in patients with schizophrenia and schizoaffective disorder: a review and meta-analysis of the literature

Cholinesterase inhibitors as adjunctive therapy in patients with schizophrenia and schizoaffective disorder: a review and meta-analysis of the literature Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

679. Antipsychotic polypharmacy is not associated with increased mortality from natural causes in patients with schizophrenia compared to monotherapy

Antipsychotic polypharmacy is not associated with increased mortality from natural causes in patients with schizophrenia compared to monotherapy Antipsychotic polypharmacy is not associated with increased mortality from natural causes in patients with schizophrenia compared to monotherapy | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how (...) in patients with schizophrenia compared to monotherapy Article Text Aetiology Antipsychotic polypharmacy is not associated with increased mortality from natural causes in patients with schizophrenia compared to monotherapy Statistics from Altmetric.com Question Question Is antipsychotic polypharmacy a risk factor for death from natural causes in patients with schizophrenia? People Case–control study nested in cohort of 27 633 patients aged 18–53 years, with ICD-8 and ICD-10 diagnosed schizophrenia

2010 Evidence-Based Mental Health

680. Second generation antipsychotics are not superior in relieving family burden in schizophrenia compared with the first generation antipsychotic perphenazine

Second generation antipsychotics are not superior in relieving family burden in schizophrenia compared with the first generation antipsychotic perphenazine Second generation antipsychotics are not superior in relieving family burden in schizophrenia compared with the first generation antipsychotic perphenazine | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time (...) in schizophrenia compared with the first generation antipsychotic perphenazine Article Text Therapeutics Second generation antipsychotics are not superior in relieving family burden in schizophrenia compared with the first generation antipsychotic perphenazine Statistics from Altmetric.com Question Question Are second generation antipsychotics superior to first generation antipsychotics for reducing family burden associated with schizophrenia? Patients 623 family caregivers of patients with schizophrenia (SCID

2010 Evidence-Based Mental Health